论文部分内容阅读
目的探讨尿液中前列腺癌基因3(PCA3)评分在血清总前列腺特异抗原(t PSA)灰区(4~10 ng/m L)的前列腺癌患者早期诊断中的应用价值。方法 t PSA灰区患者103例,其中前列腺癌患者29例(前列腺癌组)、前列腺良性增生(BPH)患者74例(BPH组)。采用荧光定量PCR法检测患者尿液中PCA3基因表达,计算尿PCA3评分,并绘制ROC曲线分析尿液PCA3评分对前列腺癌早期诊断的价值。结果前列腺癌组与BPH组比较,尿PCA3评分高,前列腺体积小(P均<0.05)。尿PCA3评分的ROC曲线下面积高于血清t PSA(P<0.05),取截断值71.5,尿PCA3评分诊断前列腺癌的敏感度及特异度分别为82.8%及81.1%。结论尿PCA3评分可提高血清t PSA灰区前列腺癌患者诊断的准确度。
Objective To investigate the value of PCA3 in the early diagnosis of prostate cancer patients with serum total prostate-specific antigen (t PSA) gray zone (4 ~ 10 ng / m L). Methods T 103 patients with gray matter area, including 29 cases of prostate cancer (prostate cancer group), benign prostatic hyperplasia (BPH) in 74 patients (BPH group). Fluorescent quantitative PCR was used to detect the expression of PCA3 in urine of patients and the urinary PCA3 score was calculated. The ROC curve was used to analyze the value of urine PCA3 score in the early diagnosis of prostate cancer. Results Compared with BPH group, urinary PCA3 score was higher in prostate cancer group and prostate volume was smaller (all P <0.05). The area under the ROC curve of urinary PCA3 score was higher than that of serum t PSA (P <0.05). The sensitivity and specificity of urine PCA3 score for diagnosing prostate cancer were 82.8% and 81.1% respectively. Conclusion Urine PCA3 score can improve the diagnostic accuracy of serum prostate cancer patients with t-PSA.